Sanofi injects 2...

Coco Sanofi plans to inject more than 2 million euros into Novodiscovery, a French clinical trial simulation specialist, to strengthen its COVID-19 trial development.
February 16th Novakiscovery, a medical technology company, announced that it had raised 2.5 million euros from Sanofi in its A2 round of financing.
funds will be used to advance work on NOVA's electronic clinical trial simulation platform, JINKO, which provides best-in-class clinical trial simulations to predict drug efficacy and optimize clinical trial development.
to run disease models in virtual patients to support decision-making and reduce clinical development risk.
, the funds will help NOVA expand into the U.S. market and work with Sanofi to develop a model of COVID-19 disease.
work process design is very similar to real-life clinical research, providing a complete set of applications from discovery to market access.
, Isabelle Vitali, Sanofi's head of global digital innovation, will join NOVA's board of directors.
NOVA, disease modeling and clinical trial simulation are increasingly being used in drug development to support decision-making.
an effective model of COVID-19 disease could be of great benefit as society struggles to address new strains and mutations, the complexity of pathophysiology of infection, and the uncertainty of changing the timetable for vaccination management.
, based in Lyon, France, has been working with medical regulators to include the technology of its research platform, also known as "electronic data", in regulatory filings.
Sanofi has now joined the technology and will use Nova to help it build a model of COVID-19 disease to support the COVID-19 vaccine and treatment efforts of the Native French population to combat the epidemic.
comes after Sanofi and partner GlaxoSmithKline (GSK) released relatively "weak" data results in the COVID-19 vaccine research and development competition at the end of 2020, forcing the two companies to postpone vaccine development until the fourth quarter of this year.
initial data, the COVID-19 vaccine failed to trigger the expected immune response in people 50 years of age and older, forcing GSK to rethink its antigen formulation.
Sanofi hopes the second attempt will be successful and has the help of the Nova platform.
for Nova, this investment partnership has increased its growing pharmaceutical customer base.
December 2020, Nova signed an agreement with Janssen Pharmaceuticals (France) for its electronic data platform.
Jansen is working on a COVID-19 vaccine for one- and two-pin agents, and while the Nova agreement does not specifically mention that it is helping Jansen with this part of the research and development, it is not difficult to predict from his cooperation with Sanofi that Jansen will be involved in this regard.
source: 1. Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work2. Novadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platform